Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.51 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CDC25A | P30304 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4619498 | 1.00 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1 | |
| SCHEMBL479563 | 1.00 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1 | |
| SCHEMBL4619726 | 1.00 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1 | |
| SCHEMBL1576782 | 0.99 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1 | |
| SCHEMBL2561609 | 0.99 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1 | |
| SCHEMBL37559 | 0.97 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1 | |
| SCHEMBL671456 | 0.97 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1 | |
| SCHEMBL479222 | 0.97 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1 | |
| SCHEMBL672371 | 0.97 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1 | |
| SCHEMBL479198 | 0.97 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458092-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| EP-3458083-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| WO-2017201352-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201350-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2010030739-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | claimed |
| WO-2010030730-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | claimed |
| WO-2008157205-A2 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2008-12-24 | — | — | WO | claimed |
| EP-1845944-A2 | PHARMACEUTICAL COMPOSITIONS | ID Biomedical Corporation of Quebec c.o.b. as Glaxosmithkline Biologicals North America (CA) | 2007-10-24 | — | — | EP | claimed |
| WO-2006086330-A2 | PHARMACEUTICAL COMPOSITIONS | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2006-08-17 | — | — | WO | claimed |
| WO-2024044728-A1 | PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023225621-A2 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | OMEGA THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023212618-A1 | LIPID NANOPARTICLES COMPRISING VENEZUELAN EQUINE ENCEPHALITIS (VEE) REPLICON AND USES THEREOF | STRAND THERAPEUTICS INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023172812-A1 | LIPOSOME-CONTAINING DIAGNOSTIC REAGENTS AND METHODS OF PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023147552-A1 | RADIOSENSITIZING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2008022046-A2 | DICER SUBSTRATE RNA PEPTIDE CONJUGATES AND METHODS FOR RNA THERAPEUTICS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007127439-A2 | COMPOSITIONS COMPRISING FUSOGENIC PROTEINS OR POLYPEPTIDES DERIVED FROM PROSAPOSIN FOR APPLICATION IN TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1845944-A2 | PHARMACEUTICAL COMPOSITIONS | ID Biomedical Corporation of Quebec c.o.b. as Glaxosmithkline Biologicals North America (CA) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006086330-A2 | PHARMACEUTICAL COMPOSITIONS | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2006-08-17 | — | — | WO | disclosed |
| EP-1458752-A2 | POLYPEPTIDES OF PSEUDOMONAS AERUGINOSA | Shire Biochem Inc. (CA) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003042240-A2 | POLYPEPTIDES OF PSEUDOMONAS AERUGINOSA | SHIRE BIOCHEM INC. (CA) | 2003-05-22 | — | — | WO | disclosed |